The influence of active transport systems on morphine -6-glucuronide transport in mdckii and MDCK-PGP cells

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 6, 2011, Pages 412-416

  Sattari, M ^a   Routledge, P A ^b   Mashayekhi, S O ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Morphine 6 glucuronide; P glycoprotein (PGP); Transport

Indexed keywords

CYCLOSPORIN; DIGOXIN; GLYCOPROTEIN P; MORPHINE 6 GLUCURONIDE; ORGANIC ANION TRANSPORTER 2; PROBENECID; SUCROSE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG PENETRATION; DRUG TRANSPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

EID: 84857425602     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stouch TR and Gudmundsson O, Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev, 2002; 54: 315-328.
2. Schinkel AH and Jonker JW, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev, 2003; 55: 3-29.
3. Lotsch J, Schmidt R, Vetter G, Schmidt H, Niederberger E, Geisslinger G and Tegeder I, Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem, 2002; 83: 241-248.
4. Wu D, Kang YS, Bickel U and Pardridge WM, Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos, 1997; 25: 768-771.
5. Oldendrof W, Hyman S, Braun L and Oldendrof S, Blood-brain barrier: Penetration of morphine, codeine, heroin, and methadone after carotid injection. Science, 1972; 178: 984.
6. Yabaluri N and Medzihradsky F, Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling. Mol Pharmacol, 1997; 52: 896-902.
7. Lotsch J, Schmidt R, Vetter G, Schmidt H, Skarke C, Niederberger E, Geisslinger G and Tegeder I, The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats. Neurosci Lett, 2002; 329: 145-148.
8. Wandel C, Kim R, Wood M and Wood A, Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology, 2002; 96: 913-920.
9. Mashayekhi S, Ghandforoush-sattari M, Hain R and Nixon L, Morphine-6-glucuronide assay using a competitive ELISA assay. Pharmaceutical Sciences, 2007; 1: 51-60.
10. Mashayekhi S, sattari M and Routledge P, Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines, Research in Pharmaceutical Sciences, 2010; 5: 119-125.
11. Mashayekhi S, Ghandforoush-Sattari M and Hain RDW, Rapid and sensitive quantitation of morphine using HPLC with electrochemical detection. Journal of Clinical Pharmacy and Therapeutics, 2008; 33: 1-9.
12. Tiberghien F and Loor F, Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs, 1996; 7: 568-578.
13. Xie R, Bouw MR and Hammarlund-Udenaes M, Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. Br J Pharmacol, 2000; 131: 1784-1792.
14. Bourasset F, Cisternino S, Temsamani J and Scherrmann JM, Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J Neurochem, 2003; 86: 1564-1567.
15. Polt R, Porreca F, Szabo LZ, Bilsky EJ, Davis P, Abbruscato TJ, Davis TP, Harvath R, Yamamura HI and Hruby VJ, Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci U S A, 1994; 91: 7114-7118.
16. Mashayekhi SO, Ghandforoush-Sattari M, Routledge PA and Hain RD, Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. Biopharm Drug Dispos, 2009; 30: 99-106.
17. Mashayekhi SO, Ghandforoush-Sattari M, Buss DC, Routledge PA and Hain RD, Impact of anti-cancer drugs and other determinants on serum protein binding of morphine 6-glucuronide. DARU J Pharm Sci, 2010 18: 107-113.
18. Mashayekhi SO, Hain RDW, Buss DC and Routledge PA, Morphine in children with cancer: impact of age,